BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Cervical cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
6 results:

  • 1. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
    Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Morphologic and Molecular Heterogeneity of cervical Neuroendocrine Neoplasia: A Report of 14 Cases.
    Ordulu Z; Mino-Kenudson M; Young RH; Van de Vijver K; Zannoni GF; Félix A; Burandt E; Wong A; Nardi V; Oliva E
    Am J Surg Pathol; 2022 Dec; 46(12):1670-1681. PubMed ID: 36069807
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic cancers.
    Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
    Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. PD-L1 expression and immune stromal features in HPV-independent cervical adenocarcinoma.
    Song F; Jia M; Yu S; Cao L; Sun PL; Gao H
    Histopathology; 2021 Nov; 79(5):861-871. PubMed ID: 34156708
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
    Carroll MR; Ramalingam P; Salvo G; Fujimoto J; Solis Soto LM; Phoolcharoen N; Hillman RT; Cardnell R; Byers L; Frumovitz M
    Int J Gynecol Cancer; 2020 Sep; 30(9):1303-1307. PubMed ID: 32727929
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.
    Spaans VM; Scheunhage DA; Barzaghi B; de Kroon CD; Fleuren GJ; Bosse T; Jordanova ES
    Gynecol Oncol; 2018 Nov; 151(2):196-201. PubMed ID: 30262404
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.